Provided by Tiger Trade Technology Pte. Ltd.

Vor Biopharma Inc.

22.85
-0.3808-1.64%
Volume:23.32K
Turnover:532.49K
Market Cap:1.35B
PE:1.98
High:22.96
Open:22.96
Low:22.68
Close:23.24
52wk High:49.95
52wk Low:6.50
Shares:59.16M
Float Shares:37.23M
Volume Ratio:2.19
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):11.53
EPS(LYR):-70.5015
ROE:-125.43%
ROA:-21.37%
PB:-6.75
PE(LYR):-0.32

Loading ...

Citi Keeps Their Buy Rating on Vor Biopharma (VOR)

TIPRANKS
·
3 hours ago

Vor Bio completes enrollment in UPSTREAM MG trial

TIPRANKS
·
Sep 08

Vor Bio Completes Enrollment in Phase 3 Upstream MG Trial for Telitacicept in Generalized Myasthenia Gravis

Reuters
·
Sep 08

Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

THOMSON REUTERS
·
Sep 08

Vor Biopharma - Upstream Mg 24-Week Primary Endpoint Results Expected in First Half of 2027

THOMSON REUTERS
·
Sep 08

Vor Bio files automatic mixed securities shelf

TIPRANKS
·
Sep 05

Vor Biopharma Inc. - Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Sep 05

Vor Bio Grants 83,600 Stock Options, 17,900 RSUs to New Hires Under Inducement Plan

Reuters
·
Sep 05

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Aug 31

Citi Remains a Buy on Vor Biopharma (VOR)

TIPRANKS
·
Aug 13

Vor Biopharma is Maintained at Neutral by Wedbush

Dow Jones
·
Aug 13

Vor Biopharma (VOR) Receives a Hold from Wedbush

TIPRANKS
·
Aug 12

Wedbush Adjusts Price Target on Vor Biopharma to $27 From $18, Keeps Neutral Rating

MT Newswires Live
·
Aug 11

Vor Biopharma Shares Drop After Q2 Results

MT Newswires Live
·
Aug 11

Vor Biopharma Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Vor Biopharma Posts Wider-than-Expected Q2 Loss on Increased G&A Costs

Reuters
·
Aug 11

Vor Biopharma Q2 EPS $(1.16) Misses $(0.70) Estimate

Benzinga Earnings
·
Aug 11

Earnings Flash (VOR) Vor Biopharma Posts Q2 Net Loss $1.16 a Share, vs. FactSet Est of $0.70 Loss

MT Newswires Live
·
Aug 11

Vor Biopharma Q2 Net Income USD -62.8 Million VS. Ibes Estimate USD -35.7 Million

THOMSON REUTERS
·
Aug 11

Press Release: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 11